Navigation Links
Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
Date:11/28/2007

Dr. Timothy Carrothers Will Present Case Example on the Value of Modeling

and Simulation to Assess Potential for QTc Prolongation

MOUNTAIN VIEW, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Timothy Carrothers, Sc.D., senior scientist, Strategic Consulting Services, has been invited to speak to members of the pharmaceutical and biotechnology industries attending the 2nd Annual Drug Information Association (DIA) Cardiac Safety Conference, to be held in Prague, Czech Republic at the Dorint Praha Don Giovanni Hotel from December 3-4, 2007.

Dr. Carrothers will present a case study on the value of model-based approaches to assess drug effects on QTc prolongation and develop future clinical studies required for new drug approval. Dr. Carrothers' presentation, "Concordance Between the Exposure-QTc Response Relationship in the Pooled Phase 1 Data vs. Thorough QTc Study", is part of a dedicated conference session led by pharmaceutical sponsors and regulators on modeling the relationship between plasma concentration of a drug and its effect on QTc prolongation as an indicator of cardiac arrhythmic risk. The session speakers will present applied research on concentration-QTc modeling and discuss perspectives for its contribution to decisions on the development, regulatory approval and labeling of new drugs. A panel discussion will also provide a forum for scientific discussion and collaborative exchange on exposure-QTc response modeling. Additional information can be found at http://www.diahome.org.

"Model-based approaches provide important tools in the analysis and reporting of QT data, which is now required by the FDA for all new drug submissions to support more informed decision-making," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "These predictive approaches integrate data across a variety of studies, allowing assessment of drug effects on QTc based on the totality of the underlying clinical data, and support trial design of QTc studies. Our scientists' collective experience with modeling QTc prolongation as an important and intensively studied measure of cardiac safety risk spans multiple indications and drug classes. Pharsight is pleased to be invited to the DIA Safety Conference, to share its perspectives on QTc modeling with industry colleagues and to exchange information on emerging trends in cardiac safety and risk assessment."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Files Application for Nasdaq Capital Market Listing
2. Pharsight to Host European Software Conference
3. Pharsight Expands Global Consulting Services Teams
4. Pharsight Achieves $7.3 Million in Quarterly Revenue
5. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
6. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
7. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
8. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
10. AtriCure to Present at Roth Capital Partners 2007 New York Conference
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... ... California and Nevada and LABS, Inc., announced the future opening of a CLIA ... screening and serology testing used to determine the suitability of potential organ ...
(Date:3/22/2017)... ... ... Wash Tower Ltd. has released a series of six viral poo-related teaser ... standalone constant pressure bidet. , The videos in the series titled "The Adventures of ... well as on its social media pages. , Each video stars Arthur the Butler ...
(Date:3/22/2017)... ... 2017 , ... The Rett Syndrome Research Trust (RSRT) announced ... afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in a ... Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving children ...
(Date:3/22/2017)... ... 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the India ... need of skilled pediatric dentistry in Rock Hill, SC, without a referral. ... treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. , ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... entered into a research collaboration to translate advances in basic neuroscience at the ... Blythedale and beyond. The collaboration seeks to improve movement, vision, and cognition impaired by ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... solutions, today reported financial and operational results for ... 31, 2016. 2016 Highlights ... compared to the full year 2015  ... year  Direct-to-consumer model launched in ...
(Date:3/22/2017)... today announced the appointment of Martyn Coombs as Chief ... ImaginAb, said "At ImaginAb we have exciting science and technology. Martyn ... business, particularly in commercializing and making step changes in the value ... our potential." ... Coombs is a recognized industry leader in nuclear medicine and imaging. ...
(Date:3/22/2017)... -- Ablation is the minimally invasive therapeutic tissue excision ... from cancerous or diseased tissue removal, to the ... fibrillation and others. The growing adoption of minimally ... and improvise existing ablation technologies for better patient ... is expected to grow at high single digit ...
Breaking Medicine Technology: